Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

NCT02519842 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Fosaprepitant
DRUG: Placebo for fosaprepitant
DRUG: Ondansetron
DRUG: Dexamethasone
DRUG: 5-HT3 antagonist

Sponsor

Merck Sharp & Dohme LLC